Common genetic variation in IGF1 and prostate cancer risk in the multiethnic cohort

Journal of the National Cancer Institute

Volumn 98, Issue 2, 2006, Pages 123-134

  Cheng, Iona ^a   Stram, Daniel O ^a   Penney, Kathryn L ^b,c,d   Pike, Malcolm ^a   Le Marchand, Loïc ^e   Kolonel, Laurence N ^e   Hirschhorn, Joel ^b,c,f   Altshuler, David ^b,c,d   Henderson, Brian E ^a   Freedman, Matthew L ^b,c,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GENETICS; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; ETHNIC DIFFERENCE; ETHNOLOGY; EXON; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICAN AMERICANS; AGED; ASIAN AMERICANS; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HAPLOTYPES; HISPANIC AMERICANS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LINKAGE DISEQUILIBRIUM; LOGISTIC MODELS; MALE; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK ASSESSMENT; UNITED STATES;

EID: 31544474588     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj013     Document Type: Article

References (50)

1. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 1995;16:3-34.
2. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 1993;53:1102-6.
3. Cohen P, Peehl DM, Lamson G, Rosenfeld RG. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 1991;73:401-7.
4. Ngo TH, Barnard RJ, Leung PS, Cohen P, Aronson WJ. Insulin-like growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: Possible mediators for the effects of diet and exercise on cancer cell survival. Endocrinology 2003;144:2319-24.
5. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM. The insulin-like growth factor axis and prostate cancer: Lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 1999;59:2203-9.
6. Ruan W, Powell-Braxton L, Kopchick JJ, Kleinberg DL. Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. Endocrinology 1999;140:1984-9.
7. DiGiovanni J, Kiguchi K, Frijhoff A, Wilker E, Bol DK, Beltran L, et al. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA 2000;97:3455-60.
8. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis. Lancet 2004;363:1346-53.
9. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099-106.
10. Nam RK, Zhang WW, Trachtenberg J, Jewett MAS, Emami M, Vesprini D, et al. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003;12:1429-37.
11. Tsuchiya N, Wang L, Horikawa Y, Inoue T, Kakinuma H, Matsuura S, et al. CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia. Int J Oncol 2005;26:225-31.
12. 19 repeat and IGFBP3-202 A/C genotypes and the risk of prostate cancer in black and white men. Cancer Epidemiol Biomarkers Prev 2005;14:403-8.
13. Li L, Cicek MS, Casey G, Witte JS. No association between genetic polymorphisms in IGF-I and IGFBP-3 and prostate cancer. Cancer Epidemiol Biomarkers Prev 2004;13:497-8.
14. Neuhausen SL, Slattery ML, Garner CP, Ding YC, Hoffman M, Brothman AR. Prostate cancer risk and IRS1, IRS2, IGF1, and INS polymorphisms: Strong association of IRS1 G972R variant and cancer risk. Prostate 2005;64:168-74.
15. Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, Pike MC, et al. A multiethnic cohort in Hawaii and Los Angeles: Baseline characteristics. Am J Epidemiol 2000;151:346-57.
16. Nickerson DA, Tobe VO, Taylor SL. PolyPhred: Automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res 1997;25:2745-51.
17. Freedman ML, Pearce CL, Penney KL, Hirschhorn JN, Kolonel LN, Henderson BE, et al. Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study. Am J Hum Genet 2005;76:82-90.
18. Haiman CA, Stram DO, Pike MC, Kolonel LN, Burtt NP, Altshuler D, et al. A comprehensive haplotype analysis of CYP19 and breast cancer risk: The Multiethnic Cohort. Hum Mol Genet 2003;12:2679-92.
19. Lewontin RC. The interaction of selection and linkage. II. Optimum models. Genetics 1964;50:757-82.
20. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-9.
21. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995;12:921-7.
22. Stram DO, Haiman CA, Hirschhorn JN, Altshuler D, Kolonel LN, Henderson BE, et al. Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 2003;55:27-36.
23. Zaykin DV, Westfall PH, Young SS, Karnoub MA, Wagner MJ, Ehm MG. Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Hum Hered 2002;53: 79-91.
24. Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G, Kaaks R. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: A prospective study in a population-based nonscreened cohort. J Clin Oncol 2004;22:3104-12.
25. Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB, Baltimore Longitudinal Study of Aging. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 2000;85:4258-65.
26. Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 1996;98:2612-5.
27. Hong Y, Pedersen NL, Brismar K, Hall K, de Faire U. Quantitative genetic analyses of insulin-like growth factor I (IGF-I), IGF-binding protein-1, and insulin levels in middle-aged and elderly twins. J Clin Endocrinol Metab 1996;81:1791-7.
28. DeLellis K, Ingles S, Kolonel L, McKean-Cowdin R, Henderson B, Stanczyk F, et al. IGF1 genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multiethnic cohort. Br J Cancer 2003;88: 277-82.
29. Gauderman WJ. Sample size requirements for association studies of gene-gene interaction. Am J Epidemiol 2002;155:478-84.
30. Easton DF. How many more breast cancer predisposition genes are there? Breast Cancer Res 1999;1:14-7.
31. Balmain A, Gray J, Ponder B. The genetics and genomics of cancer. Nat Genet 2003;33 Suppl:238-44.
32. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. (eds). SEER Cancer Statistics Review, 1975-2002, National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/ 1975_2002 [Last accessed: December 14, 2005.]
33. DeLellis K, Rinaldi S, Kaaks RJ, Kolonel LN, Henderson B, Le Marchand L. Dietary and lifestyle correlates of plasma insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3): The multiethnic cohort. Cancer Epidemiol Biomarkers Prev 2004;13:1444-51.
34. Platz EA, Pollak MN, Rimm EB, Majeed N, Tao Y, Willett WC, et al. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev 1999;8:1107-10.
35. Winter DL, Hanlon AL, Raysor SL, Watkins-Bruner D, Pinover WH, Hanks GE, et al. Plasma levels of IGF-1, IGF-2, and IGFBP-3 in white and African-American men at increased risk of prostate cancer. Urology 2001;58:614-8.
36. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994;15:80-101.
37. Giovannucci E, Pollak M, Liu Y, Platz EA, Majeed N, Rimm EB, et al. Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev 2003;12:84-9.
38. Holmes MD, Pollak MN, Willett WC, Hankinson SE. Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 2002;11: 852-61.
39. Heaney RP, McCarron DA, Dawson-Hughes B, Oparil S, Berga SL, Stern JS, et al. Dietary changes favorably affect bone remodeling in older adults. J Am Diet Assoc 1999;99:1228-33.
40. Page GP, George V, Go RC, Page PZ, Allison DB. "Are we there yet?": Deciding when one has demonstrated specific genetic causation in complex diseases and quantitative traits. Am J Hum Genet 2003;73:711-9.
41. Lander ES, Schork NJ. Genetic dissection of complex traits. Science 1994;265:2037-48.
42. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002;4:45-61.
43. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001;29:306-9.
44. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26:76-80.
45. The CHEK2 Breast Cancer Case-Control Consortium. CHEK2*1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004;74:1175-82.
46. Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 2005;6:95-108.
47. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: An approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-42.
48. Wacholder S, Rothman N, Caporaso N. Population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias. J Natl Cancer Inst 2000;92:1151-8.
49. Freedman ML, Reich D, Penney KL, McDonald GJ, Mignault AA, Patterson N, et al. Assessing the impact of population stratification on genetic association studies. Nat Genet 2004;36:388-93.
50. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-18.